Sources and Guidelines Referenced

This clinical guide references evidence-based management recommendations from major global nephrology consensus guidelines and clinical trials, including the KDIGO Clinical Practice Guideline for the Management of Glomerular Diseases (2021 update), KDIGO Guideline Updates for Lupus Nephritis and ANCA Vasculitis (2023), NICE Guideline NG203 on Chronic Kidney Disease Management (2021), European Renal Association (ERA-EDTA) Immunonephrology Working Group Guidelines (2022), the ADVOCATE Trial (Jayne et al., New England Journal of Medicine, 2021), the TESTING Trial (Lv et al., JAMA, 2022), the MENTOR Trial (Fervenza et al., New England Journal of Medicine, 2019), and the BLISS-LN Trial (Furie et al., New England Journal of Medicine, 2020).

Glomerulonephritis Management: A Comprehensive Patient Guide

1. Definition and Medical Identity

Glomerulonephritis management is a specialized clinical protocol designed to treat inflammation within the renal filtering units, known as glomeruli. Treatment combines immunosuppressive medications with protective blood pressure drugs to control immune dysfunction. The clinical goal is achieving disease remission, preventing progressive kidney failure, and preserving long-term renal function.

The medical spectrum of glomerulonephritis (inflammation of the kidney filtering units) encompasses several immune-mediated kidney disorders. In clinical practice, these disorders are divided into primary glomerular diseases, which originate natively within the kidney tissue, and secondary glomerular diseases, which stem from systemic autoimmune or infectious conditions. Medical management targets both the acute inflammatory state and chronic scarring mechanisms within the renal capillary network.

Fundamental goals of treatment include arresting immunological tissue destruction, lowering proteinuria (excess protein in the urine), controlling systemic hypertension, and maintaining a stable estimated glomerular filtration rate (a measure of overall kidney filtering capacity). Treatment pathways are guided by international nephrology standards, notably the Kidney Disease: Improving Global Outcomes (KDIGO 2021) guidelines.

2. The Underlying Condition or Need

Glomerulonephritis represents a group of immune-mediated kidney disorders characterized by structural damage to the renal capillary network. Biological injury disrupts normal blood filtration, allowing proteins and red blood cells to leak into urine. Without targeted medical management, severe glomerular inflammation leads to irreversible tissue scarring, loss of kidney function, and end-stage renal disease.

Under normal biological conditions, the glomerular filtration barrier permits metabolic waste and excess fluid to pass into the urine while retaining essential serum proteins, such as albumin, and red blood cells within the circulation. When autoimmune mechanisms disrupt this barrier, patients present with either nephrotic syndrome (a condition causing severe urine protein loss, low blood protein, and fluid swelling) or nephritic syndrome (a condition marked by urine blood loss, high blood pressure, and decreased kidney function).

Typical clinical presentation includes peripheral edema (swelling in the legs or eyelids), dark or tea-colored urine, elevated blood pressure readings, and progressive fatigue resulting from metabolic waste accumulation. If left untreated, severe glomerular inflammation triggers renal interstitial fibrosis and tubular atrophy. Studies show that unmanaged severe glomerulonephritis frequently leads to irreversible loss of kidney function within five to ten years (KDIGO 2021 Guidelines).

3. How the Treatment Works — Mechanism

Glomerulonephritis management functions by suppressing autoimmune inflammatory pathways and reducing physical stress inside kidney filtering capillaries. Immunomodulatory therapies block pathogenic antibody production, complement cascade activation, and inflammatory cell recruitment. Simultaneously, targeted blood pressure medications reduce intraglomerular hydrostatic pressure, decreasing urinary protein leakage and halting renal tissue fibrosis.

At the cellular level, immune-mediated damage occurs through circulating immune complex deposition or direct autoantibody binding to native glomerular antigens, such as the phospholipase A2 receptor (PLA2R) in membranous nephropathy (Fervenza et al., NEJM, 2019). This binding activates the complement cascade, triggering membrane attack complex formation and releasing inflammatory cytokines that injure podocytes (specialized renal filtration cells).

Therapeutic interventions target these pathways at multiple points:

• Immunosuppressive Agents: Medications such as corticosteroids (steroid anti-inflammatory drugs), cyclophosphamide, and mycophenolate mofetil inhibit lymphocyte proliferation and autoantibody secretion.
• B-Cell Depletion: Monoclonal antibodies like rituximab selectively target CD20-positive B-lymphocytes, halting pathogenic antibody generation.
• Hemodynamic Protection: Inhibition of the renin-angiotensin-aldosterone system (a hormonal pathway regulating blood pressure and fluid balance) using ACE inhibitors or ARBs reduces pressure inside the glomerular capillaries, directly decreasing protein leakage and tissue scarring (NICE NG203).
• SGLT2 Inhibition: Sodium-glucose cotransporter-2 inhibitors reduce intraglomerular pressure through tubuloglomerular feedback mechanisms, offering additive long-term kidney protection.

4. Types and Variations

Glomerulonephritis management protocols vary significantly according to the underlying histopathological subtype and disease severity identified on kidney biopsy. Treatment strategies are categorized into high-dose induction therapy to arrest active tissue destruction and lower-dose maintenance therapy to preserve remission. Selection depends on clinical presentation, antibody levels, and kidney biopsy tissue patterns.

Clinicians categorize management strategies according to specific histological diagnoses confirmed by light microscopy, immunofluorescence, and electron microscopy of renal tissue. The table below illustrates the primary disease variations, target mechanisms, and standard initial treatment protocols recommended by KDIGO 2021 clinical guidelines.

Therapeutic decisions are refined using prognostic biomarker stratification, such as urine protein excretion levels exceeding 1.0 g/day, falling estimated glomerular filtration rates, or persistent circulating autoantibody titers (Lv et al., TESTING Trial, JAMA, 2022).

5. Who the Treatment Is For — Indications

Glomerulonephritis management is indicated for adult patients diagnosed with immune-mediated glomerular diseases showing active renal inflammation or significant protein loss. Diagnosis relies on clinical evaluation, laboratory markers, and renal tissue biopsy findings. Key indications include biopsy-proven IgA nephropathy, membranous nephropathy, lupus nephritis, ANCA-associated vasculitis, and focal segmental glomerulosclerosis.

Clinical indication for medical management requires establishing clear evidence of glomerular pathology. A comprehensive clinical evaluation is performed to verify eligibility based on the following diagnostic thresholds:

• Biopsy Confirmation: Histological proof of active cellular crescents, mesangial hypercellularity, podocyte effacement, or basement membrane thickening obtained through a percutaneous renal biopsy (a needle procedure collecting kidney tissue).
• Persistent Proteinuria: Urinary protein excretion exceeding 0.5 to 1.0 grams per 24 hours despite maximum tolerated blood pressure therapy.
• Active Urinary Sediment: Presence of dysmorphic red blood cells or red blood cell casts indicating active glomerular inflammation.
• Declining Renal Function: A progressive decrease in estimated glomerular filtration rate in the presence of active autoimmune markers.
• Serological Positivity: Elevated titers of anti-neutrophil cytoplasmic antibodies (ANCA), anti-nuclear antibodies (ANA), anti-dsDNA, or anti-PLA2R antibodies.

6. Who the Treatment Is NOT For — Contraindications

Glomerulonephritis management using aggressive immunosuppressive protocols is contraindicated in patients with untreated severe infections, advanced unrecoverable chronic kidney scarring, or known drug hypersensitivities. Relative contraindications include active tuberculosis, severe liver dysfunction, uncontrolled diabetes mellitus, or severe bone marrow depression, requiring protocol modification or conservative hemodynamic management instead.

Clinicians carefully screen patients prior to initiating immunosuppressive regimens to prevent life-threatening complications. Contraindications are stratified into absolute and relative categories:

• Absolute Contraindications: Active, uncontrolled systemic infections (such as sepsis, untreated tuberculosis, or acute viral hepatitis); severe known anaphylactic hypersensitivity to primary treatment agents; and advanced kidney atrophy where biopsies reveal >80% irreversible chronic sclerosis (scarring) without active inflammation.
• Relative Contraindications: Uncontrolled diabetes mellitus (corticosteroid-induced hyperglycemia risks); severe leukopenia (white blood cell count <3,000/µL) or neutropenia; active peptic ulcer disease; pregnancy (for specific teratogenic agents like cyclophosphamide and mycophenolate mofetil); and severe hepatic impairment.

When relative contraindications exist, clinicians modify protocols by selecting non-steroid regimens, substituting less toxic agents, or relying primarily on non-immunosuppressive renoprotective therapies (KDIGO 2021 Guidelines).

7. Alternatives and Clinical Comparison

Alternatives to primary immunosuppressive management include conservative supportive therapy using blood pressure regulators and novel targeted non-immunosuppressive agents. In end-stage disease where medical therapies cannot preserve function, renal replacement modalities such as hemodialysis, peritoneal dialysis, or kidney transplantation become necessary. Treatment selection depends on underlying disease etiology and disease stage.

Evaluating management options requires comparing immunosuppressive strategies against conservative non-immunosuppressive care, therapeutic plasma exchange, and chronic renal replacement options. The table below outlines key differences across clinical parameters.

8. Pre-Treatment Phase

The pre-treatment phase of glomerulonephritis management involves comprehensive clinical evaluation, baseline diagnostic testing, and rigorous risk assessment prior to therapy initiation. Patients undergo blood tests, quantitative urine analysis, renal imaging, and a guided percutaneous kidney biopsy. Clinicians screen for underlying infections, optimize blood pressure, and establish baseline kidney function parameters.

Diagnostic workup begins with serial blood tests measuring serum creatinine, blood urea nitrogen, electrolytes, liver function, and complete blood counts. Specialized immunological testing includes serum complement levels (C3, C4), anti-nuclear antibodies (ANA), anti-double-stranded DNA (anti-dsDNA), ANCA titers, anti-PLA2R antibodies, and viral hepatitis (HBV, HCV) screening alongside HIV testing.

Quantitative urine evaluation includes a spot urine protein-to-creatinine ratio (UPCR) and a 24-hour urine collection for protein and creatinine clearance. Renal ultrasound is conducted to confirm the presence of two kidneys, assess kidney size, and exclude obstructive uropathy.

Informed consent and infection screening are crucial components. Before starting immunosuppressive agents, patients undergo screening for latent tuberculosis using an Interferon-Gamma Release Assay (IGRA) or tuberculin skin test, alongside varicella zoster screening. Prophylactic vaccinations (pneumococcal, influenza, hepatitis B, COVID-19) are administered prior to initiating intense therapy whenever clinically feasible (KDIGO 2023 Guidelines).

9. The Procedure — Step-by-Step Clinical Detail

Glomerulonephritis management follows a structured, multi-phase clinical path beginning with precise diagnostic verification and immediate therapeutic induction. Treatment transitions from hospital or clinic-based diagnostic administration to outpatient oral or intravenous pharmacological delivery. Continuous laboratory monitoring of kidney function, protein loss, and drug toxicity ensures patient safety throughout the therapeutic process.

The execution of glomerulonephritis management occurs in distinct clinical steps:

Step 1: Diagnostic Kidney Biopsy

Under local anesthesia and ultrasound guidance, a nephrologist performs a percutaneous renal biopsy using an automated core needle. Two to three tissue cores are collected to perform light microscopy, immunofluorescence, and electron microscopy. Patients lie prone and must remain on bed rest for 4 to 6 hours post-procedure to prevent bleeding complications.

Step 2: Induction Therapy Initiation

Once tissue histology is confirmed, high-dose induction therapy begins. For aggressive disease, pulse intravenous methylprednisolone (500–1,000 mg daily for 1 to 3 days) is administered in a day-care or inpatient setting, followed by high-dose oral prednisone (1 mg/kg/day). Co-administration of second-line immunosuppressive agents, such as intravenous cyclophosphamide infusions or rituximab infusions (375 mg/m² weekly for 4 doses or two 1,000 mg doses separated by 14 days), is initiated according to established subtype protocols (Stone et al., RAVE Trial, NEJM, 2010).

Step 3: Initiation of Supportive Hemodynamic Therapy

Patients receive low-dose ACE inhibitors or ARBs, titrated to maintain blood pressure below 120/80 mmHg. SGLT2 inhibitors (e.g., dapagliflozin 10 mg daily) are added to optimize protein reduction and slow filtration loss, provided estimated glomerular filtration rate is within safe prescribing limits (NICE NG203).

Step 4: Prophylactic Interventions

Patients on high-dose steroids and cytotoxic therapy begin prophylaxis against Pneumocystis jirovecii pneumonia using trimethoprim-sulfamethoxazole (800/160 mg three times weekly or single-strength daily). Proton pump inhibitors and bone-protection agents (calcium, vitamin D, bisphosphonates) are initiated to counter steroid-related complications.

Step 5: Serial Outpatient Monitoring

Outpatient surveillance involves bi-weekly or monthly evaluation of complete blood counts, metabolic profiles, urine protein-to-creatinine ratios, and specific antibody titers during the initial 3 to 6 months of induction therapy.

10. Immediate Post-Procedure Period

The immediate post-procedure period focuses on monitoring recovery after diagnostic renal biopsy and managing early responses to potent induction medications. Clinical teams observe patients for acute complications such as localized bleeding, drug hypersensitivity, or rapid metabolic changes. Initial blood pressure stabilization and symptom relief typically begin within the first 24 to 48 hours.

Following percutaneous renal biopsy, vital signs are monitored every 15 minutes for the first hour, extending to every hour for four hours. Urine color is checked for gross hematuria. Discharge occurs after 6 to 8 hours of clinical stability, provided post-biopsy ultrasound shows no expanding hematoma and hemoglobin levels remain stable.

During early pharmacological induction (first 24 to 72 hours), patients are monitored for acute medication side effects. Intravenous rituximab infusions require pre-medication with acetaminophen, diphenhydramine, and corticosteroids to mitigate infusion reactions, such as fever, chills, rash, or hypotension. Intravenous cyclophosphamide requires aggressive oral or intravenous hydration alongside mesna administration to prevent acute hemorrhagic cystitis (bladder irritation).

11. Recovery — Short and Long Term

Recovery in glomerulonephritis management spans several months to years, transitioning from acute disease stabilization to sustained clinical remission. Initial reductions in urinary protein leakage typically occur within four to twelve weeks of treatment initiation. Long-term recovery involves maintenance therapy, regular laboratory monitoring, blood pressure control, and gradual medication tapering.

The chronological timeline of recovery follows a defined clinical path:

• Weeks 1 to 4: Acute systemic inflammation resolves. Fluid accumulation decreases due to diuresis. Monitoring focuses on medication tolerance, complete blood counts (detecting early bone marrow suppression), and blood glucose levels.
• Months 1 to 3: Initial reduction in proteinuria is observed. Prednisone dosages are tapered gradually according to clinical protocols to minimize corticosteroid side effects.
• Months 3 to 6: Evaluation of clinical remission state (complete vs. partial response). Induction therapy concludes, and patients who achieve disease control transition to maintenance protocols (e.g., oral azathioprine, mycophenolate mofetil, or quarterly rituximab maintenance).
• Months 6 to 24: Maintenance phase continues. Long-term monitoring emphasizes persistent protein reduction below 0.5 g/day, blood pressure control below 120/80 mmHg, and slow reduction of maintenance immunosuppression.
• Long-Term (Beyond 2 Years): Patients remain under nephrology surveillance every 3 to 6 months to monitor for relapse, manage chronic kidney disease risk factors, and evaluate long-term cardiovascular health.

12. Risks, Side Effects, and Complications

Glomerulonephritis management carries risks related to procedure-related complications and potent immunosuppressive medication side effects. Complications range from minor post-biopsy hematomas to serious opportunistic infections, severe bone marrow suppression, steroid-induced diabetes, and organ toxicity. Close clinical surveillance, prophylactic antimicrobial therapies, and regular laboratory testing reduce these severe treatment risks.

The table below provides a stratified risk matrix categorizing potential complications by severity and frequency.

Long-term safety data from major clinical trials indicate that severe infectious complications occur in 5% to 12% of patients undergoing high-dose induction therapy (Jayne et al., ADVOCATE Trial, NEJM, 2021). Strict adherence to antimicrobial prophylaxis and routine blood counts minimizes these risks. Key warning signs requiring urgent emergency evaluation include fever above 38.0°C (100.4°F), sudden shortness of breath, severe severe flank pain, or sudden drops in urine output.

13. Lifestyle and Behavioural Considerations

Lifestyle and dietary adjustments play a crucial supportive role in glomerulonephritis management by reducing stress on compromised kidneys and controlling systemic vascular pressure. Patients must adopt a low-sodium diet, regulate dietary protein intake, maintain healthy body weight, avoid nephrotoxic substances, and abstain from smoking to maximize long-term treatment success.

Key evidence-based lifestyle modifications include:

• Sodium Restriction: Limiting daily sodium intake to under 2,000 mg (5 grams of salt) daily helps control fluid overload, reduces edema, and enhances the anti-proteinuric efficacy of ACE inhibitors and ARBs (KDIGO 2021).
• Protein Intake Optimization: Patients with non-nephrotic chronic kidney disease are advised to maintain a moderate dietary protein intake of 0.8 g/kg body weight per day to reduce hyperfiltration injury. Excessively high protein diets strain renal filtration.
• Smoking Cessation: Tobacco use accelerates renal vascular damage, increases glomerular scarring rates, and doubles the risk of progression to kidney failure.
• Avoidance of Nephrotoxins: Strict avoidance of non-steroidal anti-inflammatory drugs (NSAIDs, such as ibuprofen or naproxen), over-the-counter herbal supplements, and unmonitored radiocontrast agents is essential to prevent acute-on-chronic kidney injury.
• Cardiovascular Exercise: Engaging in 150 minutes of moderate-intensity aerobic exercise per week helps control blood pressure, improves lipid profiles, and counters steroid-induced metabolic muscle wasting.

14. How Outcomes Are Measured

Clinical outcomes in glomerulonephritis management are evaluated using quantitative lab markers, kidney biopsy tissue re-evaluation, and long-term renal survival rates. Success is defined by complete or partial disease remission, characterized by significant reduction in urinary protein excretion and stabilization of glomerular filtration. Ongoing tracking guides drug tapering and relapse detection.

Nephrologists measure treatment success using precise standardized definitions established by international consensus guidelines:

• Complete Remission: Reduction of urinary protein excretion to under 0.3 grams per 24 hours (or UPCR <300 mg/g), accompanied by stable serum creatinine levels and normal serum albumin (>3.5 g/dL).
• Partial Remission: Reduction of proteinuria by at least 50% from baseline, with total urinary protein between 0.3 and 3.5 grams per 24 hours, alongside stabilization of renal filtration.
• Treatment Relapse: Re-emergence of nephrotic-range proteinuria (>3.5 g/24 hours) or a significant rise in urinary protein levels following a period of complete or partial remission, often accompanied by an increase in specific serological antibody titers.
• Renal Survival: Long-term preservation of functional kidney tissue, avoiding a >50% decline in estimated glomerular filtration rate or progression to end-stage renal disease requiring chronic dialysis or transplantation.

If a patient fails to achieve partial remission after 3 to 6 months of optimized induction therapy, clinicians re-evaluate compliance, repeat immunological testing, or consider a repeat renal biopsy to differentiate active ongoing tissue inflammation from irreversible chronicity scarring before changing medication classes (KDIGO 2021).

15. Recent Advances and Current Standard of Care

Recent advances in glomerulonephritis management emphasize highly targeted immunomodulatory agents that reduce toxic corticosteroid exposure while improving treatment efficacy. The modern standard of care incorporates novel biological therapies, targeted complement inhibitors, and dual endothelin-angiotensin receptor antagonists, as highlighted in updated international Kidney Disease: Improving Global Outcomes clinical guidelines.

Over the past decade, therapeutic strategies have shifted from non-specific, high-dose cytotoxic drugs toward precision therapies targeting specific disease pathways:

• Targeted Complement Inhibition: Avacopan, an oral C5a receptor antagonist, has demonstrated superior efficacy in inducing remission in ANCA-associated vasculitis while significantly reducing steroid-related adverse events (Jayne et al., ADVOCATE Trial, NEJM, 2021).
• B-Cell Targeted Combination Therapy: In lupus nephritis, adding belimumab (a B-lymphocyte stimulator inhibitor) to standard immunosuppression significantly increased primary efficacy renal response rates and decreased flare frequencies (Furie et al., BLISS-LN Trial, NEJM, 2020).
• Novel Targeted Steroids: Delayed-release targeted-release budesonide delivers glucocorticoids directly to Peyer's patches in the ileum, reducing toxic systemic steroid exposure while effectively suppressing pathogenic IgA1 production in IgA nephropathy.
• Dual Receptor Antagonism: Sparsentan, a dual endothelin type A and angiotensin II receptor antagonist, has shown significant superior protein reduction compared to maximum ACE inhibitor therapy in primary focal segmental glomerulosclerosis and IgA nephropathy.

16. Common Myths and Misconceptions

Misconceptions surrounding glomerulonephritis management often lead to delayed care, inappropriate treatment cessation, or unnecessary anxiety regarding diagnostic procedures. Understanding the evidence-based realities of kidney disease, diagnostic tissue biopsy, immunosuppressive therapy, and lifestyle modification helps patients make informed healthcare decisions alongside their treating nephrology team.

Myth: Glomerulonephritis can be completely cured by taking a short course of antibiotics.
Reality: Glomerulonephritis is predominantly an autoimmune or immune-mediated inflammatory disease, not an active bacterial kidney infection. While post-streptococcal cases follow bacterial infections, management of chronic primary glomerulonephritis requires long-term immunomodulatory and protective therapies rather than simple antibiotics (KDIGO 2021).

Myth: A kidney biopsy is extremely dangerous and always causes permanent kidney damage.
Reality: Percutaneous renal biopsy under ultrasound guidance is a safe, routinely performed diagnostic procedure. Major bleeding complications requiring intervention occur in less than 0.5% of cases, and the needle core removes less than 0.1% of total functional kidney tissue while providing essential guidance for accurate treatment choices.

Myth: High blood pressure caused by kidney disease will disappear as soon as drug therapy starts.
Reality: Renal hypertension often persists even after acute inflammation resolves, as permanent vascular and tissue changes require ongoing daily blood pressure management with ACE inhibitors, ARBs, or secondary antihypertensives to protect residual filtration units.

Myth: Drinking excessive amounts of water will flush out the proteins leaking into the urine.
Reality: Drinking extra fluid does not stop glomerular protein leakage and can cause life-threatening fluid retention, peripheral swelling, and severe hypertension in patients with reduced kidney clearance. Fluid intake must be carefully tailored to renal output.

Myth: Once urine protein levels drop, immunosuppressive medications can be stopped immediately.
Reality: Abruptly stopping immunosuppressive medications frequently causes severe disease relapses and acute kidney injury. Medication doses must be tapered gradually over several months under strict nephrology surveillance.

Myth: All patients with glomerulonephritis will eventually require blood dialysis or a kidney transplant.
Reality: With early diagnostic biopsy, prompt initiation of targeted immunosuppression, and strict blood pressure management, many patients achieve long-term clinical remission and preserve normal kidney function throughout their lifetime (KDIGO 2021 Guidelines).

17. Frequently Asked Questions

What is the primary goal of glomerulonephritis management?

The main clinical goal of glomerulonephritis management is to suppress immune-mediated renal inflammation, eliminate or reduce protein leakage into the urine, preserve overall filtration function, and prevent progression to chronic end-stage kidney failure while minimizing medication side effects.

How do doctors determine which medication protocol to use?

Nephrologists choose specific treatment protocols based on microscopic evaluation of a kidney tissue biopsy, antibody levels in blood tests, total daily urine protein loss, estimated glomerular filtration rate, and the patient's individual health profile according to KDIGO clinical practice guidelines.

Why is a kidney biopsy necessary before starting treatment?

A percutaneous kidney biopsy provides exact tissue analysis using light, immunofluorescent, and electron microscopy. Because different types of glomerulonephritis present with similar clinical symptoms but require entirely different immunomodulatory drugs, histological confirmation is critical to select safe, effective therapy.

How long does immunosuppressive therapy typically last?

Immunosuppressive treatment generally includes an intensive induction phase lasting 3 to 6 months, followed by a maintenance phase lasting 12 to 24 months or longer. Medication dosages are gradually tapered as clinical remission is achieved and monitored over time.

What are the signs that glomerulonephritis treatment is working?

Positive indicators include a steady decrease in urinary protein excretion (measured via spot urine protein-to-creatinine ratio), stabilization or improvement of serum creatinine levels, reduction in leg and facial swelling, normal blood pressure control, and resolution of blood in the urine.

Can glomerulonephritis recur after achieving complete remission?

Yes, disease relapses can occur months or years after achieving initial clinical remission. Routine laboratory surveillance of blood counts, urine protein levels, and circulating antibody titers every 3 to 6 months allows early detection and prompt re-treatment of relapses.

Are corticosteroids always required in glomerulonephritis management?

Corticosteroids remain a foundational component of many induction protocols due to their rapid anti-inflammatory action. However, newer targeted therapies, such as rituximab, avacopan, and SGLT2 inhibitors, allow clinicians to reduce steroid dosages or eliminate them earlier to prevent long-term toxicity.

What dietary changes help support glomerulonephritis treatment?

Patients should adopt a low-sodium diet (<2,000 mg/day) to control blood pressure and swelling, maintain moderate protein intake (around 0.8 g/kg/day), avoid nephrotoxic herbal supplements, and abstain from alcohol and tobacco to protect kidney blood vessels.

Is it safe to exercise while receiving therapy for glomerulonephritis?

Light to moderate aerobic exercise, such as walking, swimming, or cycling, is generally encouraged once acute inflammation and severe high blood pressure are controlled. Exercise helps maintain muscular strength, counters steroid-induced weight gain, and improves cardiovascular health.

How does glomerulonephritis management differ during pregnancy?

Certain immunosuppressive drugs like cyclophosphamide and mycophenolate mofetil are teratogenic and contraindicated during pregnancy. Pregnant patients or those planning conception are transitioned to safer alternatives, such as azathioprine and tacrolimus, alongside careful blood pressure management under combined nephrology and high-risk obstetric care.

What should I do if I develop a fever while taking immunosuppressive drugs?

Developing a fever above 38.0°C (100.4°F) while on immunosuppressive therapy requires immediate medical evaluation. Because these medications suppress immune defenses, infections can progress rapidly and require urgent antibiotic treatment and temporary medication adjustments.

Can SGLT2 inhibitors be used for all types of glomerulonephritis?

SGLT2 inhibitors are recommended as additive non-immunosuppressive kidney-protective therapy for most chronic proteinuric glomerular diseases, including IgA nephropathy, provided the patient's estimated glomerular filtration rate meets prescribing guidelines (NICE NG203).

How does high blood pressure harm kidneys with glomerulonephritis?

High blood pressure increases hydrostatic force inside damaged glomerular capillary networks. This physical stress accelerates protein leakage through filtration barriers, triggers inflammation in surrounding tubular cells, and causes rapid progressive tissue scarring.